# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8010262

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

# **CONVEYING PARTY DATA**

Name	Execution Date
ALEKSANDRA FRANOVIC	04/23/2023
ERIC MARTIN	04/17/2023
NICHOL L. G. MILLER	05/09/2023
ERIC MURPHY	05/12/2023
RICHARD THOMAS WILLIAMS	05/19/2023
KEN KOBAYASHI	05/09/2023

# **RECEIVING PARTY DATA**

Name:	KINNATE BIOPHARMA INC.
Street Address:	12830 EL CAMINO REAL, SUITE 150
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92130

# **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	18296726

# **CORRESPONDENCE DATA**

Fax Number: (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (650) 493-9300

patentdocket@wsgr.com, randico@wsgr.com Email: WILSON SONSINI GOODRICH & ROSATI **Correspondent Name:** 

650 PAGE MILL ROAD Address Line 1:

Address Line 4: PALO ALTO, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	54004-738.301
NAME OF SUBMITTER:	ROSE ANDICO
SIGNATURE:	/Rose Andico/
DATE SIGNED:	06/15/2023

**Total Attachments: 12** 

**PATENT** REEL: 063967 FRAME: 0472

507963125

source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page1.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page2.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page3.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page4.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page5.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page6.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page7.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page8.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page9.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page10.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page11.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page11.tif source=Kinnate 54004-738.301 Executed Assignment as submitted for Recordation#page11.tif

PATENT REEL: 063967 FRAME: 0473

#### PATENT ASSECTABLE OF

Docket Number 54004-738,303

The undensigned:

- i. Aleksandra FRANOVIC DVI Mar. California (1)Si
- 4. Fric MilikPSty San Marros, California (US).
- J. Esic MARTIN Del Mar, California (US)
- Richard Thomas WRLLEAMS Newbury Park, California (US)
- Nichel I., G. MILLER Pewsy, California (US)
- Ken KOBAYASHI
   Ramobo Santa Fe, California (198)

(the "Secondaria"), desire in easign the easies eight, title and interest in and to the inventions and Assigned Patents (each, as defined below) to Kisman Biochanga, Ing., a corporation incorporated under the lasts of the Sints of Delangae, Seving a place of histories at 13836 El Camino Beal. Suits 131, Son Diese, California 9218/15. (for "Assigness"), and Assignes decine to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and extended consideration acknowledged by said toverhous) to have been received in full from said.

 Said Inventor(s) have invested certain new and media inventions and improvements disclosed in the Inflowing patent(s) and patent application(s):

# TREATMENT OF CANCER WITH A RAF INDIBITOR

for which application serial number 18 286-726, was filed on April 6, 2023, in the United States Patent and Trademark Office;

(the "Linux Exercises"). As used hereis: "Assigned Polants" occurs (a) the Listed Patents), (b) all Patents that share priority with or claim priority to to from the Listed Patents), including each and every Phicos that is a divisional, substitution, continuation, continuation to part, non-provisional, or assistant phase applications of any of the Listed Patents), (c) all Patents applied for an an invention dischard within the Potents included in foregoing autoclasses (a)-(b), (d) each and every Patent granting, smang or reissuing from any of the foregoing sactor subclasses (a)-(c), (e) each and every relissue, recruitmention, removal or extension of any kind of any of the foregoing under subclasses (a)-(d), and (f) each and every Patent filed outside the United Season and corresponding to any of the foregoing under subclasses (a)-(e) "Patents" means (e) patents, certifications of inventions, inventor's certification of the corresponding to any inventor of any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Patent Conversion for the Protocol of Industrial Property. The Patent Conversion Treaty or otherwise, and (ii) applications therefor (whicher provisional, converted provisional, mility, design, plant, stillly maxim, non-growing or otherwise).

- 2. Said investor(s) do barety sell, sorige, transfer and convey unto said Assignee the enter right, title and interest (a) in and to the Assigned Potents, metading the right to closin priority to and from said Assigned Potents. (b) in and so the investions disclosed in the Assigned Potents, and in and to all enhancements of the assigned Potents, and in and (c) in said to all classes for past, present and future infringeness of the Assigned Potents, including all rights to see for and to receive and recover for Assigned's own use all past, present, and future lost profits, mynities, and demages of whatever nature recoverable from an infringeness of the Assigned Potents.
- I. Said inventor(s) hereby coverant and agree to cooperate with each Assignee to enable said Assignee to enjoy to the failest extent the right, fellowed interest herein conveyed in the Cotted States. Busings comprises, or under my international execution, agreement, protocol, or treaty. Such cooperation by said inventor(s) shall include geompt production of performed facility and decreasing of testimony, execution of performers, specifications, declarations or other papers, and other assistance at it to the extens identical accessary or desirable by said Assignee (a) for performing assistance the right, title and interest herein conveyed; (b) for thing, protecting or maintaining applications for anisosance of any said Assigned Potents, (d) for interference or other priority proceedings involving said Assigned Patents or Inventions, and (e) for legal proceedings involving said inventions (r Assigned Patents, including without limitation resonance and court actions; provided, however, that reasonable expanses incurred by said inventions) in providing such cooperation stall be paid for by said Assignee.
- 4. The terms and coverages of this assignment shall impre to the benefit of used Ausignee, its successors, amigus and other legal representatives, and shall be binding upon said inventoria), their respective heirs, legal representatives and assigns.
- Said inventor(s) hereby nutriest, represent and coverant that said inventor(s) have not entered and will not content into any assignment, contract, or understanding in conflict horowith.
- 6. Said Inventoria) hereby request that any Assigned Patents issuing or granting in the United States, foorigo countries, or under any international convention, agreement, produced, or invest, be issued or granted in the name of the Assigner, or its securesors and assigns, for the sole use of said Assigner, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the lane of the State of California, without segand to condition of last principles. If any provision of this instrument is issued to be illegal or sometimesable, the other previouses shall remain effective and enforceable to the greatest extent permethed by law. This instrument may be executed as counterparts, such of which is decined at original, but all of which together constitute one and the same agreement.

Page 1 of 2

	PATENT ASSECTMENT	***************************************	Darker Signiller 54604-754 301
0	WHERE(W, said inventor(s) have executed and delive	red the interesent to said Assigner a	s of the dawn written below:
	a navouis		
Essa::	\$39 MARXXX		
Sur	Notice 1. 63. 188 (1.188)		
Owe:	ESS SELECTION		
<i>IME</i>	\$04m( 15mm 1883.185h)		
San:	Em 8:3847.4388		
RECEIVED AND AGEE		KINNATE BRIPHARMA INC.	
1800: <u>6/15/23</u>		Signature	

Docket Number 54004-738.301

The undersigned:

- Aleksandra FRANOVIC Del Mar, California (US)
- 4. Eric MURPHY San Marcos, California (US)
- 2. Eric MARTIN
  Del Mar, California (US)
- 5. Richard Thomas WILLIAMS Newbury Park, California (US)
- 3. Nichol L. G. MILLER Poway, California (US)
- Ken KOBAYASHI Rancho Santa Fe, California (US)

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Kinnate Biopharma Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 12830 El Camino Real, Suite 150, San Diego, California 92130 US, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

## TREATMENT OF CANCER WITH A RAF INHIBITOR

for which application serial number 18/296,726, was filed on April 6, 2023, in the United States Patent and Trademark Office;

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every Patent granting, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- 5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

	PATENT ASSIGNMENT		Trustina No. 22 CARRA GRADA
	* ASSISTANCE ASSISTANCE AND ASSISTAN		Docket Number 54004-738.301
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignce as of the dates written below:			
Date:	Aleksandra FRANOVIC		
Date: 4/17/2	S Enchantin		
Date:	Nichol L. G. MILLER		
Date:	Eric MURPHY		
Date:	Richard Thomas WILLIAMS		
Date:	Ken KOBAYASHI		
RECEIVED AND AG	REED TO BY ASSIGNEE:	KINNATE BIOPHARMA INC.	
Date: (0/13/	7.3	Signature: Mark Meltz Name: Mark Meltz Title: Chief Operating Officer	r & General Counsel

# **BEST COPY**

### PATENT ASSIGNMENT

Docket Number 54004-738.301

The undersigned:

- Aleksandra FRANOVIC Del Mar, California (US)
- 4. Eric MURPHY
  San Marcos, California (US)
- 2. Eric MARTIN
  Del Mar, California (US)
- 5. Richard Thomas WILLIAMS Newbury Park, California (US)
- 3. Nichol L. G. MILLER Poway, California (US)
- 6. Ken KOBAYASHI Rancho Santa Fe, California (US)

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Kinnate Biopharma Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 12830 El Camino Real, Suite 150, San Diego, California 92130 US, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

## TREATMENT OF CANCER WITH A RAF INHIBITOR

for which application serial number 18/296,726, was filed on April 6, 2023, in the United States Patent and Trademark Office;

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every Patent granting, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- 5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT		Docket Number 54004-738.301	
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:			
Date:	Aleksandra FRANOVIC		
Date:	Eric MARTIN		
Date: <u>5/4/2023</u>	Nichol L. G. MILLER		
Date:	Eric MURPHY		
Date:	Richard Thomas WILLIAMS		
Date:	Ken KOBAYASHI		
RECEIVED AND AGREE	ED TO BY ASSIGNEE:	KINNATE BIOPHARMA INC.	
Date: 6/15/	<u> 23</u>	Signature:  Name: Mark Meltz  Title: Chief Operating Officer	& General Counsel

Docket Number 54004-738.301

The undersigned:

- Aleksandra FRANOVIC Del Mar, California (US)
- 4. Eric MURPHY San Marcos, California (US)
- Eric MARTIN
   Del Mar, California (US).
- 5. Richard Thomas WILLIAMS Newbury Park, California (US)
- Nichol L. G. MILLER Poway. California (US)
- 6. Ken KOBAYASHI Rancho Santa Fe, California (US)

(the "Inventor(s)"), desire to assign the entire right, fittle and interest in and to the Inventions and Assigned Patents (each, as defined below) to Kinnate Biopharma Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 12830 El Camino Real, Suite 159, San Diego, California 92130 US, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

 Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

## TREATMENT OF CANCER WITH A RAF INHIBITOR

for which application serial number 18/296,726, was filed on April 6, 2023, in the United States Patent and Trademark Office;

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s). (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, resemination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (l) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of prefection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property. The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assigned the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents, (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of pertinest specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said assigned Patents or Inventions; and (e) for legal proceedings involving said inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said inventor(s), their respective heirs, legal representatives and assigns.
- Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT			Docket Number 54004-738.301
IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:			
Lease:	Aleksaedra FRANOVIC		
Date:	Erk MARTIN		
Date.	Nichol L @ MILLER		
Date: \$\f\12\f202\}	Bric MURPRY		
Date:	Richard Thomas WILLIAMS		
Date:	Ken KOBAYASHI		
RECEIVED AND AGRE	ED TO BY ASSIGNEE: KINNATE BIO	PHARMA INC.	
Date: 6/15/2	Signature: Name: Mar Title: Chi		& General Counsel

Docket Number 54004-738.301

The undersigned:

- Aleksandra FRANOVIC
   Del Mar, California (US)
- 4. Eric MURPHY San Marcos, California (US)
- 2. Eric MARTIN Del Mar, California (US)
- 5. Richard Thomas WILLIAMS Newbury Park, California (US)
- 3. Nichol L. G. MILLER Poway, California (US)
- 6. Ken KOBAYASHI Rancho Santa Fe, California (US)

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Kinnate Biopharma Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 12830 El Camino Real, Suite 150, San Diego, California 92130 US, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

### TREATMENT OF CANCER WITH A RAF INHIBITOR

for which application serial number 18/296,726, was filed on April 6, 2023, in the United States Patent and Trademark Office;

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, invention's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- 5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

	PATENT ASSIGNMENT	Docket Number 54004-738,301	
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:			
Date:	Aleksandra FRANOVIC		
Date:	Eric MARTIN		
Date:	Nichol L. G. MILLER		
Date:	Eric MLRPHY		
Date: 5/79/2423	Richard Thomas WILLIAMS		
Date:	Ken KOBAYASHI		
RECEIVED AND AGREED TO BY ASSIGNEE: KINNATE BIOPHARMA INC.			
Date: 6/5/3	Signature: Name: Mark Meltz Title: Chief Operating	Officer & General Counsel	

Docket Number 54004-738,301

The undersigned.

- Aleksandra FRANOVIC Del Mar, California (US)
- Eric MURPHY
   San Marcos, California (US)
- Eric MARTIN Del Mar, California (US)
- Richard Thomas WiLLIAMS Newbury Park, California (US)
- Nichol L. G. MILLER Poway, California (US)
- Ken KOBA YASHI
   Rancho Santa Fe, California (US)

the "Inventor(sf"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Kinnate Biopharma inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 12830 El Camino Real, Suite 150, San Diego, California 92130 US. (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignce:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patents) and patent application(s):

## TREATMENT OF CANCER WITH A RAF INHIBITOR

for which application serial number 18/296,726, was filed on April 6, 2023, in the United States Patent and Trademark Office;

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b). (d) each and every Patent graming, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty of otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, fitle and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said inventor(s) (the "<u>Inventions</u>") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, mysities, and damages of whatever nature recoverable from an intringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or destrable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall mure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said inventor(s), their respective horrs, legal representatives and assigns
- Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict here with.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, he issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

	PATENT ASSIGNMENT		Docket Number 54004-738.301
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below			
Date:	Aleksandra FRANOVIC		
Date:	Ene MARTIN		
Date:	Nichoi U. G. MILLER		
Date:	Eric MUBPRY		
Date:	Richard Thomas WB. CIAMS		
Date 3/9/2023	K. KOBA VASHI		
RECEIVED AND AGRIN	ED TO BY ASSIGNEE:	Signature: Name: Mark Melri Title: Chief Operating Office	r & General Counsel